Skip to main content

Table 3 Summarized toxicities data of studies

From: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Events

Grade 3/4, No.(%)

OR (95%CI)

p value

Capecitabine group

(N = 954)

Control group

(N = 926)

HFS

124 (13.0)

0 (0.0)

139.44 (24.43–5555.92)

< 0.001

Neutropenia

137 (14.4)

118 (12.7)

1.13 (0.87–1.48)

0.31

Abdominal pain/diarrhea

18 (1.9)

3 (0.3)

5.92 (1.85–18.88)

< 0.001

Nausea

9 (0.9)

4 (0.4)

2.19 (0.71–6.74)

0.27

Vomiting

17 (1.8)

9 (1.0)

1.85 (0.84–1.08)

0.09

Fatigue

18 (1.9)

2 (0.2)

5.92 (1.85–18.88)

< 0.001

Overall

435 (45.6)

304 (32.8)

1.71 (1.42–2.07)

< 0.001